European Immunization Week 2018- Statement of Guido Rasi, Executive Director, European Medicines Agency

Posted on: 26/04/2018 - 13:27

Vaccines matter for each of us: yearly, they prevent 2.7 million people from contracting measles, one million from getting whooping cough and two million babies from getting tetanus. They eradicated smallpox. They stopped polio, a dreadful disease affecting millions of children, in almost all... more

Field of Interest: European Union Medical News
Type: News Feed

Human medicines European public assessment report (EPAR): Movymia, teriparatide, Date of authorisation: 11/01/2017, Revision: 13, Status: Authorised

Submitted by Anonymous (not verified) on 22 April 2026 - 16:22

Human medicines European public assessment report (EPAR): Movymia, teriparatide, Date of authorisation: 11/01/2017, Revision: 13, Status: Authorised

Orphan designation: 3-(4-((7-Cyano-1-methyl-2-((1-methyl-2-oxo-5-(trifluoromethyl)-1,2-dihydropyridin-3-yl)amino)-1H-imidazo[4,5-b]pyridin-6-yl)oxy)pyridin-2-yl)-1,1-dimethylurea Treatment of myelofibrosis, 20/04/2026 Positive

Submitted by Anonymous (not verified) on 22 April 2026 - 15:48

Orphan designation: 3-(4-((7-Cyano-1-methyl-2-((1-methyl-2-oxo-5-(trifluoromethyl)-1,2-dihydropyridin-3-yl)amino)-1H-imidazo[4,5-b]pyridin-6-yl)oxy)pyridin-2-yl)-1,1-dimethylurea Treatment of myelofibrosis, 20/04/2026 Positive

Orphan designation: adeno-associated virus serotype SLB101 containing the human microdystrophin gene Treatment of Duchenne muscular dystrophy, 20/04/2026 Positive

Submitted by Anonymous (not verified) on 22 April 2026 - 15:47

Orphan designation: adeno-associated virus serotype SLB101 containing the human microdystrophin gene Treatment of Duchenne muscular dystrophy, 20/04/2026 Positive

Human medicines European public assessment report (EPAR): Vyndaqel, tafamidis, Date of authorisation: 16/11/2011, Revision: 32, Status: Authorised

Submitted by Anonymous (not verified) on 22 April 2026 - 15:42

Human medicines European public assessment report (EPAR): Vyndaqel, tafamidis, Date of authorisation: 16/11/2011, Revision: 32, Status: Authorised

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Latest Newsletters

More